Lakefront Biotherapeutics Eyes 2027 Trials for Autoimmune Drug, Backed by €2.2 Billion in Cash

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) is preparing to expand testing of its autoimmune drug candidate gamgertamig, with executives pointing to clinical data, potential registrational trials and a sizable cash balance as the company moves beyond its former cell therapy focus.

Speaking at the Jefferies Global Healthcare Conference, Chief Executive Henry Gosebruch said Lakefront has substantially wound down the cell therapy programs it previously operated as Galapagos. Those programs had been consuming about $300 million a year, and the company did not believe they had a commercial future, he said.

Lakefront and Gilead acquired Ouro Medicines in June, adding gamgertamig, a BCMAxCD3 T-cell engager, to Lakefront’s portfolio. Gosebruch said the drug’s clinical data had continued to mature since the company released an abstract accepted for presentation at the American Society of Hematology, or ASH, meeting.

Testing the potential for durable remission

Chief Medical Officer Eric Hedrick said gamgertamig is designed to deplete both B cells and plasma cells, with the goal of producing a sustained remission after those immune cells return. In the ASH abstract, the majority of patients who responded during immune cell depletion retained their response after immune reconstitution, he said.

Hedrick said longer follow-up will be important to establish the durability of those remissions. He described immune thrombocytopenia, or ITP, as probably the lead indication, and said the aim is to provide a limited course of treatment that produces a durable, treatment-free remission.

Lakefront has indicated that registrational development could begin as early as 2027 in ITP and warm autoimmune hemolytic anemia, or wAIHA. Hedrick said the company intends to discuss trial designs with regulators and believes it has much of the information needed to design Phase 3 studies, although it will continue to monitor remission durability.

Gosebruch said an existing basket study includes myositis, Sjögren’s and pemphigus. The company plans to start additional basket studies in neurologic and endocrine diseases in the first half of next year, he said. More mature data and a larger patient count are expected at the ASH Congress, while additional investigator-initiated data may be published next year.

Gilead partnership and cash position

Gosebruch said Gilead paid for half of the Ouro acquisition and will be the commercialization partner for the acquired programs. Lakefront would receive royalties, he said, while the companies agreed to a 50-50 profit split for the preclinical programs through commercialization.

Chief Financial Officer Aaron Cox said Lakefront will fund preregistrational work and split registrational trial costs equally with Gilead. He said the company had €2.2 billion in cash and expects inflows including €20 million to €25 million in annual royalties and approximately €125 million in aggregate tax refunds over five years.

Cox said Lakefront’s estimate of at least €1.6 billion remaining after funding its portfolio through a first approval could also accommodate additional indications. He added that the company completed a €50 million share buyback in October and had launched another €50 million buyback the day before the conference discussion.

Gosebruch said Lakefront is open to further acquisitions, particularly assets with clear clinical proof of concept and development programs that can advance efficiently. Autoimmune diseases remain a priority, he said, but the company is not in a rush to complete another deal.

About Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.